General Announcement::Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
19-Aug-2019 15:09:42
Status
New
Announcement Sub Title
Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride
Announcement Reference
SG190819OTHRSCVG
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
19/08/2019 12:39:00
Description (Please provide a detailed description of the event in the box below)
Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride for adults with type 2 diabetes in India

Attachments

SGX_PR_19.08.2019 SIGNED.pdf
Total size =3366K